News Pharma furious as UK Statutory Scheme rebate rate soars The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.
R&D Life Sciences Industry Report - Part 7 The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Market Access Overcoming barriers for global CGT adoption Cell and gene therapies (CGT) have emerged as the next big thing in medicine, holding the power to deliver cures where none previously existed.
News Lyfegen partners EVERSANA on pricing, access resource Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.
News Study finds big life expectancy deficit in adults with ADHD UK study finds adults with ADHD have a big shortfall in life expectancy, raising questions about diagnosis rates and treatment access.
Patients Tackling inappropriate prescription practices for weight los... A critical issue within the pharmaceutical sector has been highlighted by the MHRA’s investigation into the improper prescription of Wegovy.
News MSD licenses Lp(a) heart drug from Hengrui in $2bn deal MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl